CN108936669A - Improve the composition and the preparation method and application thereof of memory - Google Patents
Improve the composition and the preparation method and application thereof of memory Download PDFInfo
- Publication number
- CN108936669A CN108936669A CN201811113938.9A CN201811113938A CN108936669A CN 108936669 A CN108936669 A CN 108936669A CN 201811113938 A CN201811113938 A CN 201811113938A CN 108936669 A CN108936669 A CN 108936669A
- Authority
- CN
- China
- Prior art keywords
- composition
- memory
- improving
- nicotinamide
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000015654 memory Effects 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 229950006238 nadide Drugs 0.000 claims abstract description 21
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 20
- 230000006872 improvement Effects 0.000 claims abstract description 13
- -1 s- Ademetionine Chemical compound 0.000 claims abstract description 13
- 241000208340 Araliaceae Species 0.000 claims abstract description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 235000008434 ginseng Nutrition 0.000 claims abstract description 10
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 10
- 229930182490 saponin Natural products 0.000 claims abstract description 10
- 150000007949 saponins Chemical class 0.000 claims abstract description 10
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims abstract description 7
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 6
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 6
- 108010024137 Nicotinamide-Nucleotide Adenylyltransferase Proteins 0.000 claims description 18
- 102000015597 Nicotinamide-nucleotide adenylyltransferase Human genes 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 14
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 239000000287 crude extract Substances 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 230000006798 recombination Effects 0.000 claims description 8
- 238000005215 recombination Methods 0.000 claims description 8
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000001530 fumaric acid Substances 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 235000011087 fumaric acid Nutrition 0.000 claims description 6
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 6
- 239000000347 magnesium hydroxide Substances 0.000 claims description 6
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 235000021317 phosphate Nutrition 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000000811 xylitol Substances 0.000 claims description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 6
- 229960002675 xylitol Drugs 0.000 claims description 6
- 235000010447 xylitol Nutrition 0.000 claims description 6
- 229910021485 fumed silica Inorganic materials 0.000 claims description 5
- 210000004907 gland Anatomy 0.000 claims description 5
- 229940100515 sorbitan Drugs 0.000 claims description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 235000012254 magnesium hydroxide Nutrition 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 240000006927 Foeniculum vulgare Species 0.000 claims 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000002490 cerebral effect Effects 0.000 abstract description 5
- 239000001301 oxygen Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 abstract 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 abstract 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 abstract 1
- 229920001287 Chondroitin sulfate Polymers 0.000 abstract 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 abstract 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 abstract 1
- 229960001570 ademetionine Drugs 0.000 abstract 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 abstract 1
- 229940022405 astaxanthin Drugs 0.000 abstract 1
- 235000013793 astaxanthin Nutrition 0.000 abstract 1
- 239000001168 astaxanthin Substances 0.000 abstract 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract 1
- 229940059329 chondroitin sulfate Drugs 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- 229940087603 grape seed extract Drugs 0.000 abstract 1
- 235000002532 grape seed extract Nutrition 0.000 abstract 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract 1
- 229960003080 taurine Drugs 0.000 abstract 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 abstract 1
- 229960001661 ursodiol Drugs 0.000 abstract 1
- 239000001717 vitis vinifera seed extract Substances 0.000 abstract 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000212314 Foeniculum Species 0.000 description 6
- 239000006137 Luria-Bertani broth Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000026139 Memory disease Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000006984 memory degeneration Effects 0.000 description 3
- 208000023060 memory loss Diseases 0.000 description 3
- 235000020956 nicotinamide riboside Nutrition 0.000 description 3
- 239000011618 nicotinamide riboside Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000057234 Acyl transferases Human genes 0.000 description 2
- 108700016155 Acyl transferases Proteins 0.000 description 2
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100246038 Mus musculus Ptpn5 gene Proteins 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 1
- 229960001227 oxiracetam Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutical technology fields, provide a kind of composition and the preparation method and application thereof for improving memory.A kind of composition improving memory comprising nicotinamide adenine dinucleotide, taurine, phosphatidylserine, ginsenoside PPD, ginseng saponin Rh 2, chondroitin sulfate, ursodesoxycholic acid, Sialic acid, s- Ademetionine, γ-aminobutyric acid, astaxanthin, grape seed extract, pyroglutamic acid ester.The composition of the improvement memory accelerates cerebral blood circulation to cerebral oxygen supply amount is improved, and improving memory has very big effect, and prescription is simple, cheap.The present invention also provides the preparation method of the composition of the improvement memory and applications.
Description
Technical field
The present invention relates to pharmaceutical technology field more particularly to a kind of composition and preparation method thereof for improving memory with answer
With.
Background technique
Memory is reflection of the human brain to the things lived through.People that we met or object, the sound listened, the gas smelt
Taste, the taste tasted, handled thing, the problem of thinking deeply, the mood experienced and emotion etc. can all be stayed in brains
Lower trace, and show under certain condition, here it is memories.In daily life, oneself recent memory power is such as found very much not
It is forgetful, forget the thing just done etc. as in the past, often do not remembered thing, here it is the failure of memory that we often say,
Medically, referred to as " amnesia ".Memory loss be it is multifactor, if the elderly brain aging degenerate, the malnutrition of children
Etc. a variety of situations.Currently, the health food of improvement memory in the market is mostly by fish oil (main component EPA, DHA), lecithin
The composition such as rouge, amino acid.Though above-mentioned each health food technically respectively has one's own knack, and to certain sides of memory loss
Face has certain health-care effect, but on the whole, generally existing following deficiency: 1, prevents the effect of memory loss from not showing
It writes.2, only there is certain health-care effect, it is unobvious to improve memory effect.3, formula is more single, is difficult have various aspects
Synergistic effect, cannot have simultaneously enhancing cerebral function, delay brain aging, improve human immunological competence, improve insomnia forgetfulness,
Neurasthenia, senile dementia symptom and improve intelligence the effect of.
Prevention and treatment memory disorder or the drug of decline have much both at home and abroad, and such as current clinically used Oxiracetam and pyrrole are drawn
Western smooth etc., they are, to reach enhancing memory, to improve learning ability but purpose by improving brain metabolism.But these are changed
The adverse reaction that drug more or less there are people can not accept is learned, and is currently only used for cerebral injury and caused nervous function
It lacks, the treatment of memory and disturbance of intelligence, it can not be to universal decrease of memory crowd's medication.Also have on domestic and international market at present
The product of some brain boosting and supplementings, but it is most of have the defects that it is ineffective or complex in composition.
Summary of the invention
It is an object of the invention to overcome the above-mentioned prior art, provide it is a kind of improve memory composition and its
Preparation method and application.
In order to solve the above technical problems, invention uses technical solution as described below.A kind of composition improving memory,
It includes following component:
Preferably, the composition for improving memory further includes the bulk pharmaceutical chemicals of 1-10 parts by weight, and the bulk pharmaceutical chemicals include
One or more of Radix Polygalae, Semen Cuscutae, fructus gleditsiae, rhizoma anemarrhenae, semen ziziphi spinosae, fennel seeds, folic acid.
Preferably, the bulk pharmaceutical chemicals are including at least in Radix Polygalae, Semen Cuscutae, fructus gleditsiae, rhizoma anemarrhenae, semen ziziphi spinosae, fennel seeds, folic acid
Four kinds.
Preferably, the composition for improving memory further includes the auxiliary material of 1-10 parts by weight, and the auxiliary material includes Ni Bo
Golden complex ester, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty acid ester, magnesium stearate, crosslinking carboxylic first
One or more of base sodium cellulosate, magnesium hydroxide, pregelatinated shallow lake, calcium sulfate, fumed silica, lactose.
Preferably, the auxiliary material include at least Nipagin complex esters, fumaric acid, phosphate, xylitol, microcrystalline cellulose,
Sorbitan fatty acid ester, magnesium stearate, croscarmellose sodium, magnesium hydroxide, pregelatinated shallow lake, calcium sulfate, gas phase
Three kinds in silica, lactose.
Preferably, the nicotinamide adenine dinucleotide, ginsenoside PPD, the weight ratio between ginseng saponin Rh 2 are
3-7:5-7:2-5.
Preferably, the nicotinamide adenine dinucleotide, ginsenoside PPD, the weight ratio between ginseng saponin Rh 2 are
5:7:3.
It is a kind of improve memory composition preparation method, according to the composition of above-mentioned improvement memory each component and
It prepares and uniformly mixes.
Preferably, the preparation method of the composition for improving memory further includes the system of nicotinamide adenine dinucleotide
It is standby；The preparation of the nicotinamide adenine dinucleotide include: extract nicotinamide-nucleotide adenylyltransferase crude extract or its
Pure enzyme；
The crude extract or its pure enzyme of immobilization recombination nicotinamide-nucleotide adenylyltransferase；
It is catalyzed with immobilization recombination nicotinamide-nucleotide adenylyltransferase, with nicotinamide nucleotide and trinosin
Nicotinamide adenine dinucleotide is prepared for substrate.
A kind of application for the composition improving memory, is used to prepare health care for the composition of above-mentioned improvement memory
Product.
The beneficial effects of the present invention are:
(1) it acts synergistically between each substance of component of the present invention, to cerebral oxygen supply amount is improved, accelerates cerebral blood circulation,
Improving memory has very big effect, and prescription is simple, cheap.This pharmaceutical composition is inventor in long-term practice
In to TCM Recipe art combination modern crafts develop meticulously as a result, to improve memory have apparent therapeutic effect, clinic see
It examines, for therapeutic effect up to 97.5%, the primary crude drug of preparation is botanical medicine, provides optimal guarantor for Drug safety
Barrier, the medicament research and development for also treating hyperlipidemia for Chinese medicine open new world.
(2) present invention adds PPD, ginseng saponin Rh 2 in above-mentioned side, the two ingredients have improving studing ability
Effect, this mainly with PPD, ginseng saponin Rh 2 improve brain blood supply it is related, the removing to oxygen radical is also that it changes
One of the mechanism of kind brain learning memory capability, above-mentioned side association make the improvement of brain memory ability with PPD, ginseng saponin Rh 2
With stronger.
(3) inventor is on the basis of conventional formulation, be put forward for the first time plus with nicotinamide adenine dinucleotide (NADH) and
The theory of the specific effective component such as PPD, ginseng saponin Rh 2, and using the theory as guiding theory, pass through a large amount of pharmacological evaluations.
In existing report, NADH, PPD, Rh2 three are only used separately as raw material, not yet retrieve any be total to three at present
With the composition using preparation, traditional Chinese and western medicine theory of the present invention is mutually echoed, and the introducing that all kinds of specific auxiliary materials are added can be mentioned significantly
Other medicinal materials have facilitation effect to memory is improved in high side, and above several components produce synergistic function, pass through tune
With so that the effect of each component obtained the technical effect of 1+1 > 2.
(4) the present invention overcomes the vacancy for the food for improving memory in current food service industry, medicine can especially be substituted
The vacancy of the health care product of the raising memory of object.
Specific embodiment
To make those skilled in the art that the purposes, technical schemes and advantages of invention be more clearly understood, below
Invention is further elaborated by embodiment.
Embodiment one
A kind of composition improving memory comprising following component:
Preferably, the composition for improving memory comprising following component:
Wherein, the nicotinamide adenine dinucleotide, ginsenoside PPD, the weight ratio between ginseng saponin Rh 2 are 3-
7:5-7:2-5, optimal is 5:7:3.
In some preferred embodiments, the composition of the improvement memory further includes the raw material of 1-10 parts by weight
Medicine, the bulk pharmaceutical chemicals include one or more of Radix Polygalae, Semen Cuscutae, fructus gleditsiae, rhizoma anemarrhenae, semen ziziphi spinosae, fennel seeds, folic acid.More
Good, the bulk pharmaceutical chemicals are including at least four kinds in Radix Polygalae, Semen Cuscutae, fructus gleditsiae, rhizoma anemarrhenae, semen ziziphi spinosae, fennel seeds, folic acid.
Specifically, the bulk pharmaceutical chemicals are made of Radix Polygalae, fructus gleditsiae, rhizoma anemarrhenae, fennel seeds, folic acid.
In some preferred embodiments, the composition of the improvement memory further includes the auxiliary material of 1-10 parts by weight,
The auxiliary material include Nipagin complex esters, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty acid ester,
Magnesium stearate, croscarmellose sodium, magnesium hydroxide, pregelatinated shallow lake, calcium sulfate, fumed silica, one in lactose
Kind is several.It is preferred that the auxiliary material includes at least Nipagin complex esters, fumaric acid, phosphate, xylitol, microcrystalline cellulose
Element, sorbitan fatty acid ester, magnesium stearate, croscarmellose sodium, magnesium hydroxide, pregelatinated shallow lake, calcium sulfate, gas
Three kinds in aerosil, lactose.Specifically, the auxiliary material is by Nipagin complex esters, fumaric acid, phosphate, microcrystalline cellulose
Element, sorbitan fatty acid ester, magnesium stearate, croscarmellose sodium, fumed silica, lactose composition.
Embodiment two
A kind of preparation method for the composition improving memory, according to the composition for improving memory described in embodiment one
Each component and proportion prepare and uniformly mix.
In some preferred embodiments, the preparation method of the composition of the improvement memory further includes nicotinoyl amine gland
The preparation of purine dinucleotides；The preparation of the nicotinamide adenine dinucleotide includes: to extract nicotinamide riboside adenylyl to turn
Move the crude extract or its pure enzyme of enzyme；
The crude extract or its pure enzyme of immobilization recombination nicotinamide-nucleotide adenylyltransferase；
It is catalyzed with immobilization recombination nicotinamide-nucleotide adenylyltransferase, with nicotinamide nucleotide and trinosin
(ATP) nicotinamide adenine dinucleotide is prepared for substrate.
Specific step is as follows:
By the plasmid pRSET bmj transformed competence colibacillus bacterial cell of niacinamide-containing nucleosides adenylyl transferase gene
E.coliHB101 is cultivated 24 hours at upper 37 DEG C of Luriabroth (LB) plate (kanamycins containing 100mg/L).Inoculation is single
Be cloned in 5 milliliters of LB liquid mediums (kanamycins containing 100mg/L) in 30 DEG C culture 20-24 hours.Bacterium is collected by centrifugation
Body, and be suspended in 1 milliliter of 100mM Tris hydrochloride buffer (pH7.5).Then ultrasonic treatment bacterial cell is used.Centrifugation
(10 DEG C, 17,800g, 10 minutes) simultaneously collect supernatant, as thick leach protein (or crude extract).The nicotinamide riboside gland of recombination
Glycosides acyltransferase thick leach protein is heat-treated 10 minutes through 70 DEG C, is centrifuged (10 DEG C, 17,800g, 10 minutes) and is collected supernatant, i.e.,
For partially purified albumen.
Nicotinamide-nucleotide adenylyltransferase immobilization
Nicotinamide-nucleotide adenylyltransferase thick leach protein or partially purified albumen are taken, with washing enzyme buffer liquid
(0.02MTris HCl/0.001MEDTA, pH7.0 solution) is diluted to protein content 5-10mg/ml.Enzyme dilution is molten with PB
Liquid (2.0mol/L potassium dihydrogen phosphate, pH7.5) mixes in equal volume, and (10 milligrams of epoxy type fixed enzyme vector LX 3000 is added
Enzyme/gram carrier), it is reacted 20 hours for 25 DEG C in shaking table (revolving speed 100rpm).Sock filtration is used after the reaction was completed, with washing enzyme buffer
Liquid cleans 56 times, obtains immobilization nicotinamide-nucleotide adenylyltransferase.
Nicotinamide adenine dinucleotide is prepared with immobilization nicotinamide-nucleotide adenylyltransferase
Preparation substrate solution: the trinosin (ATP) of nicotinamide nucleotide, 10mmol/L containing 5mmol/L,
The MgCl of 100mmol/LTris hydrochloride buffer and final concentration of 10mmol/L2, adjust pH to 7.5.1 milliliter of substrate solution is taken,
Then 0.05 gram of immobilization nicotinamide-nucleotide adenylyltransferase is added, reaction 2-20 hours is carried out in 37 DEG C.Centrifugation (10 DEG C,
17800g, 15 minutes) and collect supernatant.Nicotinamide adenine in the supernatant as obtained by high pressure liquid chromatography (HPLC) measurement
The content of dinucleotides.As a result, the conversion ratio that nicotinamide nucleotide is converted into nicotinamide adenine dinucleotide is more than 80%.
Several specific preparation methods are provided below
Preparation method 1:
First dried supplementary material is crossed into 30-80 mesh respectively, keep distribution of particle sizes uniform, mobility is more preferable, former auxiliary
Material keeps drying, and the raw material screened is then carried out proportion weighing, is warming up to after adding water that mixing is sufficiently stirred at 25-40 DEG C
After 50 DEG C are stirred 1 hour, composition is obtained.
Preparation method 2:
First dried supplementary material is crossed into 60 meshes respectively, keep distribution of particle sizes uniform, mobility is more preferable, and supplementary material is protected
Drying is held, the raw material screened is then subjected to proportion weighing, while relevant auxiliary materials are added, stirred evenly.The sample that will be mixed
Product are pelletized in granulator, and are dried and then carry out whole grain.It is subsequently placed into tablet press machine, adjusts tablet press machine parameter,
Tabletting is carried out, theoretical slice weight is 500mg, finally carries out film coating, inspection and packaging.
Preparation method 3:
(1) it prepares content: dried supplementary material being crossed into 60 meshes respectively first, supplementary material keeps drying, then will
The raw material screened carries out proportion weighing, while relevant auxiliary materials are added, and uniformly.
(2) prepared by soft capsule body: now glycerol and water are added in glue pot, are then separately added into gelatin and relevant auxiliary materials,
Flexible glue utricule is made in stirring, vacuum outgas.
(3) it prepares capsule: above-mentioned prepared content and flexible glue utricule being dried by pelleting, sizing, ball is washed, dries in the air
Ball picks up ball and packaging and other steps, and soft capsule is made.
Preparation method 4:
S1: taking optional component to be broken into coarse granule, adds 5 times of 70% ethyl alcohol heating and refluxing extraction 2h of amount, filtration；The dregs of a decoction add 3 again
70% ethyl alcohol heating and refluxing extraction 1h of amount again, filtration, filtrate merge, and recycle ethyl alcohol and are simultaneously concentrated under reduced pressure into relative density at 60 DEG C
1.35~1.40 thick paste, it is spare；
The resulting product of step 1: being added the water of 7 times of amounts by S2, and heating and refluxing extraction volatile oil 4h divides the volatilization for taking layering
Oil, it is spare；The dregs of a decoction and medical fluid coarse filtration, filtrate centrifuge separation, supernatant and the dregs of a decoction save backup respectively；
S3: the dregs of a decoction merge after the volatile oil for taking essential component to obtain with S2 step, add water to cook extract it is secondary, for the first time plus
18 times of amount water extract 2h, and second plus 12 times of amount water extract 1h, coarse filtration, filtrate centrifuge separation, the supernatant and S2 extracted twice
What step obtained extracts the supernatant merging after volatile oil, is concentrated under reduced pressure into the thick paste of relative density 1.35~1.40 at 60 DEG C,
It is spare；
S4: taking dextrin, superfine silica gel powder, mixes, is added to the water concentrate contracting thick paste that above-mentioned S1 step obtains and obtains with S3 step
To alcohol extracting concentration thick paste in, stir, laying, be dried in vacuo, crush, dextrin is added, spray into S2 step and obtain
Volatile oil is sieved, and mixes, and is packed into capsule.
Embodiment three
A kind of application for the composition improving memory, the composition for improving memory described in embodiment one is used to make
Standby health care product.
Specific embodiment is provided below and is tested
One, preparation improves the composition of memory
Embodiment 1
Each component are as follows:
Wherein, bulk pharmaceutical chemicals are made of Radix Polygalae, fructus gleditsiae, rhizoma anemarrhenae, fennel seeds, folic acid；Auxiliary material is by Nipagin complex esters, rich horse
Acid, phosphate, microcrystalline cellulose, sorbitan fatty acid ester, magnesium stearate, croscarmellose sodium, gas phase dioxy
SiClx, lactose composition.Nicotinamide adenine dinucleotide is prepared using following methods:
By the plasmid pRSET bmj transformed competence colibacillus bacterial cell of niacinamide-containing nucleosides adenylyl transferase gene
E.coliHB101 is cultivated 24 hours at upper 37 DEG C of Luriabroth (LB) plate (kanamycins containing 100mg/L).Inoculation is single
Be cloned in 5 milliliters of LB liquid mediums (kanamycins containing 100mg/L) in 30 DEG C culture 20-24 hours.Bacterium is collected by centrifugation
Body, and be suspended in 1 milliliter of 100mM Tris hydrochloride buffer (pH7.5).Then ultrasonic treatment bacterial cell is used.Centrifugation
(10 DEG C, 17,800g, 10 minutes) simultaneously collect supernatant, as thick leach protein (or crude extract).The nicotinamide riboside gland of recombination
Glycosides acyltransferase thick leach protein is heat-treated 10 minutes through 70 DEG C, is centrifuged (10 DEG C, 17,800g, 10 minutes) and is collected supernatant, i.e.,
For partially purified albumen.
Nicotinamide-nucleotide adenylyltransferase immobilization
Nicotinamide-nucleotide adenylyltransferase thick leach protein or partially purified albumen are taken, with washing enzyme buffer liquid
(0.02MTris HCl/0.001MEDTA, pH7.0 solution) is diluted to protein content 5-10mg/ml.Enzyme dilution is molten with PB
Liquid (2.0mol/L potassium dihydrogen phosphate, pH7.5) mixes in equal volume, and (10 milligrams of epoxy type fixed enzyme vector LX 3000 is added
Enzyme/gram carrier), it is reacted 20 hours for 25 DEG C in shaking table (revolving speed 100rpm).Sock filtration is used after the reaction was completed, with washing enzyme buffer
Liquid cleans 56 times, obtains immobilization nicotinamide-nucleotide adenylyltransferase.
Nicotinamide adenine dinucleotide is prepared with immobilization nicotinamide-nucleotide adenylyltransferase
Preparation substrate solution: the trinosin (ATP) of nicotinamide nucleotide, 10mmol/L containing 5mmol/L,
The MgCl of 100mmol/LTris hydrochloride buffer and final concentration of 10mmol/L2, adjust pH to 7.5.1 milliliter of substrate solution is taken,
Then 0.05 gram of immobilization nicotinamide-nucleotide adenylyltransferase is added, reaction 2-20 hours is carried out in 37 DEG C.Centrifugation (10 DEG C,
17800g, 15 minutes) and collect supernatant.Nicotinamide adenine in the supernatant as obtained by high pressure liquid chromatography (HPLC) measurement
The content of dinucleotides.As a result, the conversion ratio that nicotinamide nucleotide is converted into nicotinamide adenine dinucleotide is more than 80%.
Embodiment 2
The difference from embodiment 1 is that:
Each component are as follows:
Embodiment 3
The difference from embodiment 1 is that:
Each component are as follows:
Embodiment 4
The difference from embodiment 1 is that:
Each component are as follows:
Two, effect detection
1, the experimental provision of mouse step down test step dow n test is a rectangle reflective box, and major diameter is divided by black plastic plate
Several sections, bottom paving are the copper grid of 5mm with spacing, can lead to electric current appropriate (32V alternating current).Each small section has one
High and diameter is the chain-wales of 4.5cm.When experiment, mouse is placed on copper grid first, when copper grid are powered, is jumped on copper grid
Mouse shocked by electricity, normal reaction is to hide electric shock to jump onto platform, most mouse be possible to again or repeatedly to jump off platform by
To electric shock, platform can be snapped back when being shocked by electricity again.So training 5min, and it is (wrong by the number to shock by electricity to record every mouse
Accidentally number), as school grade.It tests after for 24 hours, when this time testting, mouse is placed on diving tower first again, record is for the first time
Errors number in time (incubation period) for jumping off, the number of animals and 5min to be shocked by electricity reflects that memory keeps situation with this.
Experiment and grouping: being experimental group 1-4, commercially available also shellfish soothing soft capsule according to the composition that embodiment 1-4 is prepared
For experimental group 5, the blank capsule casing material of embodiment 1 is experimental group 6.Every group of 10 mouse.Every mouse is pressed after mouse adapts to environment
Stomach-filling is measured according to 25mg/kg, control group gives 0.1ml physiological saline stomach-filling.It is jumped respectively before administration and after administration 24 hours
Platform test.
As a result as shown in the table
2, clinical test is each according to 1200mg by the composition of embodiment 1, provides 30-40 years old adult 3 times a day,
Continuous 7 days, it is divided into two groups of every group of 10 people, control group gives blank control, carries out Blind Test.Record test front and back memory state, knot
Fruit experimental group self-induction memory is obviously improved, and control group does not have significant change.
The above is only a preferred embodiment of the present invention, protection scope of the present invention is not limited merely to above-mentioned implementation
Example, all technical solutions belonged under thinking of the present invention all belong to the scope of protection of the present invention.It should be pointed out that for the art
Those of ordinary skill for, several improvements and modifications without departing from the principles of the present invention, these improvements and modifications
It should be regarded as protection scope of the present invention.
Claims (10)
1. a kind of composition for improving memory, it is characterised in that: it includes following component:
2. improving the composition of memory as described in claim 1, it is characterised in that: further include the raw material of 1-10 parts by weight
Medicine, the bulk pharmaceutical chemicals include one or more of Radix Polygalae, Semen Cuscutae, fructus gleditsiae, rhizoma anemarrhenae, semen ziziphi spinosae, fennel seeds, folic acid.
3. as claimed in claim 2 improve memory composition, it is characterised in that: the bulk pharmaceutical chemicals include at least Radix Polygalae,
Semen Cuscutae, fructus gleditsiae, rhizoma anemarrhenae, semen ziziphi spinosae, fennel seeds, four kinds in folic acid.
4. improving the composition of memory as described in claim 1, it is characterised in that: it further include the auxiliary material of 1-10 parts by weight,
The auxiliary material include Nipagin complex esters, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty acid ester,
Magnesium stearate, croscarmellose sodium, magnesium hydroxide, pregelatinated shallow lake, calcium sulfate, fumed silica, one in lactose
Kind is several.
5. improving the composition of memory as claimed in claim 4, it is characterised in that: the auxiliary material is multiple including at least nipalgin
It is fine to close ester, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty acid ester, magnesium stearate, cross-linked carboxymethyl
Tie up plain sodium, magnesium hydroxide, pregelatinated shallow lake, calcium sulfate, fumed silica, three kinds in lactose.
6. the composition of the improvement memory as described in claim any one of 1-5, it is characterised in that: the nicotinoyl amine gland is fast
Nicotinamide adenine dinucleotide, ginsenoside PPD, the weight ratio between ginseng saponin Rh 2 are 3-7:5-7:2-5.
7. improving the composition of memory as claimed in claim 6, it is characterised in that: the two nucleoside of nicotinamide adenine
Acid, the weight ratio between ginsenoside PPD, ginseng saponin Rh 2 are 5:7:3.
8. a kind of preparation method for the composition for improving memory, it is characterised in that: remember according to improving described in claim 1
The each component and proportion of the composition of power are prepared and are uniformly mixed.
9. improving the preparation method of the composition of memory as claimed in claim 8, it is characterised in that: further include nicotinoyl amine gland
The preparation of purine dinucleotides；
The preparation of the nicotinamide adenine dinucleotide include: extract nicotinamide-nucleotide adenylyltransferase crude extract or its
Pure enzyme；
The crude extract or its pure enzyme of immobilization recombination nicotinamide-nucleotide adenylyltransferase；
It is catalyzed with immobilization recombination nicotinamide-nucleotide adenylyltransferase, using nicotinamide nucleotide and trinosin the bottom of as
Object prepares nicotinamide adenine dinucleotide.
10. a kind of application for the composition for improving memory, it is characterised in that: by improvement memory described in claim 1
Composition is used to prepare health care product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811113938.9A CN108936669A (en) | 2018-09-25 | 2018-09-25 | Improve the composition and the preparation method and application thereof of memory |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811113938.9A CN108936669A (en) | 2018-09-25 | 2018-09-25 | Improve the composition and the preparation method and application thereof of memory |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108936669A true CN108936669A (en) | 2018-12-07 |
Family
ID=64472006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811113938.9A Withdrawn CN108936669A (en) | 2018-09-25 | 2018-09-25 | Improve the composition and the preparation method and application thereof of memory |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108936669A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112167638A (en) * | 2020-06-29 | 2021-01-05 | 武汉林宝莱生物科技有限公司 | Plant antioxidant formula and preparation method |
| WO2021031536A1 (en) * | 2019-08-20 | 2021-02-25 | 泓博元生命科技（深圳）有限公司 | Use of nadh and/or nmn in preparing medicaments and health care products for brain function recovery |
| CN116584655A (en) * | 2023-05-22 | 2023-08-15 | 陕西中科通大生命科学技术有限公司 | A nutritional composition for improving brain intelligence, and its preparation method |
| WO2024071360A1 (en) * | 2022-09-30 | 2024-04-04 | 株式会社明治 | Composition for promoting brain function development in infants |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1136436A (en) * | 1996-01-09 | 1996-11-27 | 包仕尧 | Tablet for clearing head for cerebrorascular disease |
| CN1985993A (en) * | 2006-12-29 | 2007-06-27 | 淮北市辉克药业有限公司 | Compound preparation for enhancing memory |
| CN101214322A (en) * | 2007-12-27 | 2008-07-09 | 天津市弗兰德医药科技发展有限公司 | Grape seed extract micropills and preparation thereof |
| CN101313751A (en) * | 2008-06-23 | 2008-12-03 | 广州蓝钥匙海洋生物工程有限公司 | Health food for auxiliary improvement of memory |
| CN101658233A (en) * | 2009-09-07 | 2010-03-03 | 汕头市新特医药有限公司 | Tablet candy and producing method thereof |
| CN102018716A (en) * | 2009-09-14 | 2011-04-20 | 王泽君 | Medical application of protopanaxatriol and protopanaxadiol in nervous system diseases |
| CN105497093A (en) * | 2015-12-30 | 2016-04-20 | 青岛银色世纪健康产业集团有限公司 | Composition with auxiliary memory improvement function, preparation method of composition and capsule containing composition |
| CN106074577A (en) * | 2016-06-30 | 2016-11-09 | 重庆帅旭科技发展有限公司 | For improving functional type alimentation composition and the application thereof of memory |
-
2018
- 2018-09-25 CN CN201811113938.9A patent/CN108936669A/en not_active Withdrawn
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1136436A (en) * | 1996-01-09 | 1996-11-27 | 包仕尧 | Tablet for clearing head for cerebrorascular disease |
| CN1985993A (en) * | 2006-12-29 | 2007-06-27 | 淮北市辉克药业有限公司 | Compound preparation for enhancing memory |
| CN101214322A (en) * | 2007-12-27 | 2008-07-09 | 天津市弗兰德医药科技发展有限公司 | Grape seed extract micropills and preparation thereof |
| CN101313751A (en) * | 2008-06-23 | 2008-12-03 | 广州蓝钥匙海洋生物工程有限公司 | Health food for auxiliary improvement of memory |
| CN101658233A (en) * | 2009-09-07 | 2010-03-03 | 汕头市新特医药有限公司 | Tablet candy and producing method thereof |
| CN102018716A (en) * | 2009-09-14 | 2011-04-20 | 王泽君 | Medical application of protopanaxatriol and protopanaxadiol in nervous system diseases |
| CN105497093A (en) * | 2015-12-30 | 2016-04-20 | 青岛银色世纪健康产业集团有限公司 | Composition with auxiliary memory improvement function, preparation method of composition and capsule containing composition |
| CN106074577A (en) * | 2016-06-30 | 2016-11-09 | 重庆帅旭科技发展有限公司 | For improving functional type alimentation composition and the application thereof of memory |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021031536A1 (en) * | 2019-08-20 | 2021-02-25 | 泓博元生命科技（深圳）有限公司 | Use of nadh and/or nmn in preparing medicaments and health care products for brain function recovery |
| CN112167638A (en) * | 2020-06-29 | 2021-01-05 | 武汉林宝莱生物科技有限公司 | Plant antioxidant formula and preparation method |
| WO2024071360A1 (en) * | 2022-09-30 | 2024-04-04 | 株式会社明治 | Composition for promoting brain function development in infants |
| CN116584655A (en) * | 2023-05-22 | 2023-08-15 | 陕西中科通大生命科学技术有限公司 | A nutritional composition for improving brain intelligence, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108936669A (en) | Improve the composition and the preparation method and application thereof of memory | |
| CN104826087B (en) | Compound Moringa polypeptide and its preparation method and application | |
| CN108112999A (en) | For supplying dietary fat method, composition and device that acid needs | |
| CN109170891A (en) | A kind of composition and the preparation method and application thereof improving memory | |
| CN104435257B (en) | It is a kind of to help to reduce composition of cholesterol and preparation method thereof, preparation and application | |
| CN106377533A (en) | Trepang phospholipid and application thereof to increment of motor coordination ability of organism | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| CN101524422A (en) | Health products with hypolipemic function, preparation method and usage thereof | |
| CN108378368A (en) | It is a kind of that there is the composition and preparation method thereof for improving memory function | |
| CN104491048B (en) | A kind of loquat leaf total sesquiterpene glucoside extract and preparation method and application | |
| CN101422544A (en) | Haifei capsule formulation with weight reduction function and preparation method thereof | |
| CN101779791B (en) | Composition with health care functions and preparation method thereof | |
| CN107537028B (en) | Formula for simultaneously assisting in reducing blood sugar and blood pressure and preparation method thereof | |
| CN103690821B (en) | A kind of auxiliary antilipemic compositions | |
| CN110269915A (en) | A kind of Weight-reducing and lipid-lowering composition and preparation method thereof | |
| CN108651993A (en) | A kind of male health-care composition, preparation and the preparation method and application thereof | |
| CN109453267A (en) | Sobering-up composition and the preparation method and application thereof | |
| CN100360179C (en) | Medicine for treating infantile anorexia | |
| CN101822683A (en) | Medical care application of L-arabinose composition | |
| CN104000877A (en) | Blood glucose reducing composition and application thereof | |
| CN106754427A (en) | Thermophilic blue spore pore fungi new strains and its acclimation method | |
| CN102499322A (en) | Novel health-care food or drug with function of improving memory | |
| CN105770098A (en) | Blood pressure reducing composition and application thereof | |
| CN105232676B (en) | A kind of Chinese medicine for treating diabetes and preparation method thereof | |
| CN109091663A (en) | A kind of antianaphylactic composition and the preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181207 |